Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Market Cap & Net Worth: Larimar Therapeutics Inc (LRMR)
Larimar Therapeutics Inc (NASDAQ:LRMR) has a market capitalization of $453.73 Million ($453.73 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14399 globally and #5794 in its home market, demonstrating a -23.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Larimar Therapeutics Inc's stock price $4.38 by its total outstanding shares 103590392 (103.59 Million).
Larimar Therapeutics Inc Market Cap History: 2015 to 2026
Larimar Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $7.82 Billion to $453.73 Million (-28.19% CAGR).
Index Memberships
Larimar Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #383 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1372 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.01% | #205 of 263 |
Weight: Larimar Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Larimar Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Larimar Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LRMR by Market Capitalization
Companies near Larimar Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Larimar Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Larimar Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Larimar Therapeutics Inc's market cap moved from $7.82 Billion to $ 453.73 Million, with a yearly change of -28.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $453.73 Million | +14.96% |
| 2025 | $394.68 Million | -1.55% |
| 2024 | $400.89 Million | -14.95% |
| 2023 | $471.34 Million | +10.17% |
| 2022 | $427.83 Million | -61.72% |
| 2021 | $1.12 Billion | -49.60% |
| 2020 | $2.22 Billion | +60.74% |
| 2019 | $1.38 Billion | -77.58% |
| 2018 | $6.15 Billion | +7.14% |
| 2017 | $5.74 Billion | +45.28% |
| 2016 | $3.95 Billion | -49.44% |
| 2015 | $7.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Larimar Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $453.73 Million USD |
| MoneyControl | $453.73 Million USD |
| MarketWatch | $453.73 Million USD |
| marketcap.company | $453.73 Million USD |
| Reuters | $453.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.